Vanda Pharmaceuticals
VNDA
179 hedge funds and large institutions have $867M invested in Vanda Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 60 increasing their positions, 72 reducing their positions, and 12 closing their positions.
133% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 12
23% more capital invested
Capital invested by funds: $704M → $867M (+$164M)
7% more funds holding
Funds holding: 168 → 179 (+11)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.32% less ownership
Funds ownership: 99.45% → 99.13% (-0.32%)
17% less repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 72
79% less call options, than puts
Call options by funds: $738K | Put options by funds: $3.55M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WG
Winton Group
London,
United Kingdom
|
+$8.01M |
| 2 |
Prudential Financial
Newark,
New Jersey
|
+$4.71M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$4.64M |
| 4 |
BlackRock
New York
|
+$4.63M |
| 5 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$3.91M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$10.9M |
| 2 |
Millennium Management
New York
|
-$6.78M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$5.49M |
| 4 |
State Street
Boston,
Massachusetts
|
-$5.02M |
| 5 |
Goldman Sachs
New York
|
-$4.65M |
VNDA Hedge Fund Activity: Q4 2019 in Review
179 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q4 2019, worth a combined $867M — up 23% from $704M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new VNDA positions and 12 closed out — a net gain of 16 holders — while 60 added to existing stakes and 72 trimmed.
The largest buyer was Winton Group, adding an estimated $8.01M. The largest seller was Armistice Capital, cutting an estimated $10.9M.
- 179 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q4 2019, up from 168 in Q3 2019.
- Funds reported $867M of Vanda Pharmaceuticals stock for Q4 2019, up 23% quarter-over-quarter.
- 28 funds opened new Vanda Pharmaceuticals positions in Q4 2019 and 12 closed out, a net change of +16 holders.
- The largest Vanda Pharmaceuticals buyer in Q4 2019 was Winton Group, an estimated $8.01M added.
- The largest Vanda Pharmaceuticals seller in Q4 2019 was Armistice Capital, an estimated $10.9M sold.
Based on aggregated 13F filings for Q4 2019.